UroGen Pharma Ltd (URGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, UroGen Pharma Ltd (URGN) has a cash flow conversion efficiency ratio of 0.249x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-33.01 Million) by net assets ($-132.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see UroGen Pharma Ltd (URGN) total market value for the company's overall valuation and market capitalisation.
UroGen Pharma Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how UroGen Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
UroGen Pharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of UroGen Pharma Ltd ranked by their cash flow conversion efficiency. Explore UroGen Pharma Ltd earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Feng Tay Enterprises Co Ltd
TW:9910
|
0.069x |
|
Sinocelltech Group Ltd
SHG:688520
|
0.137x |
|
Medical Properties Trust, Inc.
NYSE:MPT
|
-0.003x |
|
Tokai Carbon Korea Co. Ltd
KQ:064760
|
0.019x |
|
Titan Wind Energy Suzhou
SHE:002531
|
0.018x |
|
LTC Properties Inc
NYSE:LTC
|
0.049x |
|
Guangdong Feinan Resources Recycling Co Ltd
SHE:301500
|
N/A |
|
CENTRAL PUERTO ADR/1 AP1
F:C3TA
|
0.074x |
Annual Cash Flow Conversion Efficiency for UroGen Pharma Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of UroGen Pharma Ltd from 2013 to 2025. View UroGen Pharma Ltd stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-105.47 Million | $-162.44 Million | 1.540x | -85.99% |
| 2024-12-31 | $-8.80 Million | $-96.77 Million | 10.992x | +838.56% |
| 2023-12-31 | $-65.21 Million | $-76.38 Million | 1.171x | +19.53% |
| 2022-12-31 | $-89.36 Million | $-87.56 Million | 0.980x | +109.71% |
| 2021-12-31 | $8.41 Million | $-84.89 Million | -10.091x | -818.23% |
| 2020-12-31 | $96.36 Million | $-105.89 Million | -1.099x | -179.00% |
| 2019-12-31 | $180.30 Million | $-71.02 Million | -0.394x | +4.95% |
| 2018-12-31 | $90.09 Million | $-37.33 Million | -0.414x | -196.64% |
| 2017-12-31 | $68.52 Million | $-9.57 Million | -0.140x | -154.38% |
| 2016-12-31 | $16.31 Million | $4.19 Million | 0.257x | +161.41% |
| 2015-12-31 | $17.15 Million | $-7.17 Million | -0.418x | +64.76% |
| 2014-12-31 | $3.47 Million | $-4.12 Million | -1.187x | -27.26% |
| 2013-12-31 | $2.74 Million | $-2.56 Million | -0.933x | -- |
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder… Read more